TLX (Telix Pharmaceuticals) ROCE %: 4.95% (As of Dec. 2025)


TLX Telix Pharmaceuticals Ltd TLX
50 GF Score
Price $10.90
GF Value $27.71
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Telix Pharmaceuticals ROCE %?

Telix Pharmaceuticals TLX +6.76% 50 ROCE % is 4.95% as of Dec. 2025. GuruFocus rates TLX with a GF Score™ of 50/100 and a GF Value™ of $27.71 (Possible Value Trap). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Telix Pharmaceuticals's annualized ROCE % for the quarter that ended in Dec. 2025 was 4.95%.

Telix Pharmaceuticals  (NAS:TLX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Telix Pharmaceuticals ROCE % Related Terms

Telix Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Telix Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Telix Pharmaceuticals ROCE % Chart

Telix Pharmaceuticals Annual Data
Trend Sep00 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -69.02 -74.70 8.20 13.77 4.22

Telix Pharmaceuticals Semi-Annual Data
Sep00 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.57 23.16 12.66 3.09 4.95
TLX
50GF Score
Telix Pharmaceuticals Ltd TLX
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Telix Pharmaceuticals ROCE % Calculation

Telix Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=35.15/( ( (940.379 - 205.088) + (1163.986 - 231.624) )/ 2 )
=35.15/( (735.291+932.362)/ 2 )
=35.15/833.8265
=4.22 %

Telix Pharmaceuticals's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=45.156/( ( (1189.952 - 298.582) + (1163.986 - 231.624) )/ 2 )
=45.156/( ( 891.37 + 932.362 )/ 2 )
=45.156/911.866
=4.95 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 4.95% mean?
Telix Pharmaceuticals (TLX) has a ROCE % of 4.95% as of Dec. 2025.
Is Telix Pharmaceuticals' ROCE % too high?
Telix Pharmaceuticals' current ROCE % is 4.95%. Overall, Telix Pharmaceuticals has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Telix Pharmaceuticals' ROCE % compare to VRTX and REGN?
Telix Pharmaceuticals' ROCE % of 4.95% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Telix Pharmaceuticals's current ROCE % is 4.95%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telix Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Telix Pharmaceuticals (TLX) is currently considered Possible Value Trap. The stock's GF Value™ is $27.71, compared to a current price of $10.90 — trading 60.7% below its estimated fair value. The current ROCE % is 4.95%. Telix Pharmaceuticals' overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Telix Pharmaceuticals (TLX), the current ROCE % is 4.95% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Telix Pharmaceuticals (TLX) Overvalued in 2026?

Based on GuruFocus' analysis, Telix Pharmaceuticals stock appears to be undervalued. The current stock price of $10.90 is trading 60.7% below its estimated GF Value™ of $27.71. GuruFocus considers Telix Pharmaceuticals to be Possible Value Trap.

Key valuation signals for TLX:

  • ROCE %: 4.95%
  • GF Value™: $27.71 vs. price of $10.90 (60.7% below fair value)
  • GF Score™: 50/100 with 6 warning signs

No single metric tells the full story. See the TLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Telix Pharmaceuticals Business Description

Address 55 Flemington Road, Level 4, North Melbourne, Melbourne, VIC, AUS, 3051
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
50GF Score

Get the complete analysis for TLX

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.90
Price
$27.71
GF Value